| Document |
Document Title |
|
WO/2020/068562A1 |
Methods of treating infections caused by free-living amoeba are disclosed. The methods generally include systemic administration of an effective amount of miltefosine, such as an oral or intravenous formulation, and optionally local admi...
|
|
WO/2020/061279A1 |
The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPK1) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, P. falciparum, C...
|
|
WO/2020/058385A1 |
The invention concerns a rinsable oily suspension of submicron colloidal mineral particles dispersed on a submicroscopic scale, the rinsable oily suspension comprising: - a lipophilic dispersing phase - a surfactant or a combination of a...
|
|
WO/2020/053365A2 |
Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2020/054712A1 |
A compound represented by formula (1), formula (2), or formula (3) or a salt thereof, or an N-oxide thereof.
|
|
WO/2020/053364A1 |
Compounds of formula I (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, can be used as insecticides.
|
|
WO/2020/054821A1 |
The present invention addresses the problem of developing, by focusing on the central role of group 2 innate lymphoid cells (ILC2) in the immune system, a drug that is capable of inhibiting the activity of ILC2. The present invention has...
|
|
WO/2020/051689A1 |
The present application relates to the treatment of nematode infections. For example, the application relates to the use of compounds of Formula (III) as defined herein for treatment of a nematode infection or a disease, disorder or cond...
|
|
WO/2020/053509A1 |
The invention relates to a family of analogue compounds of squalamine for their use as a drug, in particular for treating or for preventing mycobacterial infections, in particular tuberculosis. A further aim of the present invention is n...
|
|
WO/2020/050212A1 |
The present invention addresses the problem of providing a heteroaryl azole compound that has an excellent pest controlling activity, in particular, an insecticidal activity and/or acaricidal activity, and high safety and can be industri...
|
|
WO/2020/051408A1 |
The present disclosure is directed to methods for preventing or treating helminth (e.g., filarial) diseases in animals. The methods are accomplished by administering to the animal a therapeutically effective amount of an inhibitor of UDP...
|
|
WO/2020/050403A1 |
This method for preventing muscle melting that occurs in the muscles of Salmoniformes is characterized in that a microsporidian expellant containing a benzimidazole-based compound as an active component is administered. The microsporidia...
|
|
WO/2020/047991A1 |
Use of an anti-acarid additive in daily chemical products. Diaryl lactam compounds have excellent anti-acarid effects, and can be used in applications such as anti-acarid body wash, anti-acarid facial cleaners and anti-acarid daily chemi...
|
|
WO/2020/051130A1 |
Described herein are methods and compositions for reducing transmission of Plasmodium to a female mosquito. Aspects of the invention relate to contacting to a mosquito with a Plasmodium transmission blocking compound. Another aspect of t...
|
|
WO/2020/043708A1 |
This invention relates to a kit comprising the components lactic acid, insulin and glucose, and optionally one or more components selected from a glucagon inhibitor, an alpha-beta adrenergic blocker and an antidiabetic agent, for treatin...
|
|
WO/2020/043831A1 |
The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof useful as inhibitors of Cyclophilins and modulators of cyclophilin-like proteins. The invention also relates to uses of said compound...
|
|
WO/2020/038821A1 |
The invention relates to glutarimide compounds of formula I, (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use ...
|
|
WO/2020/037438A1 |
The invention relates to a pharmaceutical composition with antineoplastic and antitumour action, and a method for obtaining same, wherein said composition comprises structured lipid nanoparticles that have a diameter of 0.1 nm to 100 nm,...
|
|
WO/2020/028977A1 |
The present disclosure relates to a controlled release complex of a carboxylated polymer having carboxyl groups having a degree of substitution of about 0.1 to about 1.0, forming a complex through ionic interaction with an antimalarial a...
|
|
WO/2020/024060A1 |
Provided herein are methods and compositions useful for inhibiting microbe growth. The methods can comprise contacting the microbe with an antimicrobial agent and bicarbonate. In some embodiments, provided herein are methods for treating...
|
|
WO/2020/025683A1 |
The invention relates to injectable prolonged-action compositions for use in the treatment of nail diseases, including potentially promoting the growth of the nail, or for use promoting the growth of the nail.
|
|
WO/2020/014745A1 |
The present invention provides a composition for human or animal consumption, preferably with antiviral, antibacterial, antifungal, antiprotozoal, immune boosting and/or toxin resistance activities. The composition includes a fungal extr...
|
|
WO/2020/016235A1 |
The present invention relates to compounds of formula (1a), (1b), (1c), (1d) or (1e) and pharmaceutically acceptable salts or solvates thereof for use in the treatment or prevention of fascioliasis. Some of these compounds are novel per ...
|
|
WO/2020/013147A1 |
Provided are: a benzimidazole compound represented by general formula (1) {wherein R1 represents a hydrogen atom or cyano group; R2 represents a (C1-C6)alkyl group, a (C1-C6)alkoxy(C1-C6)alkyl group, or a halo(C1-C6)alkyl group; R repres...
|
|
WO/2020/014068A1 |
A compound of formula (I), (IA) or formula (II) or a composition comprising the compound of formula (I), (IA) or formula (II) in association with a veterinarily acceptable carrier are described. A method of controlling helminths using sa...
|
|
WO/2020/012044A1 |
The invention relates to a method for preparing a nano-structured material of a silicate having a laminar, fibrilar or tubular structure with praziquantel, a compound with antiparasitic activity. Other aspects of the invention relate to ...
|
|
WO/2020/011808A1 |
A compound of formula (I), wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds, which can be used as insecticides.
|
|
WO/2020/012406A1 |
The present invention relates to solid oral pharmaceutical compositions comprising spinosad for controlling an ectoparasite infestation on a companion animal. It provides a process for the preparation of said compositions. It also provid...
|
|
WO/2020/010398A1 |
The present invention broadly relates to stable emulsion compositions comprising allylisothiocyanate and the use thereof. The emulsion compositions may comprise water, allylisothiocyanate, one or more surfactants and an oil other than al...
|
|
WO/2020/007704A1 |
The present invention relates to novel halogen-substituted compounds, to processes for their preparation and to their use for controlling animal pests, in particular arthropods and especially insects and arachnids.
|
|
WO/2020/002593A1 |
This present application relates to compounds (and salts thereof) that are generally useful as anthelmintic agents. This invention also relates to uses of the compounds and salts to make medicaments, and treatments comprising the adminis...
|
|
WO/2020/000111A1 |
The present disclosure provides acaricidal compounds, i.e. compounds 3c {3,6}, 3c {4,6}, 3c {3, 3}, 3c{4,3}and 3c {6,6}, that are effective in killing Varroa destructor mites while being harmless to honey bees.
|
|
WO/2020/006392A1 |
Compositions and methods for treating Trichomoniasis using topically administered antibiotics such as aminoglycosides, including streptomycin, spectinomycin, kanamycin A, amikacin, tobramycin, dibekacin, gentamicin, sisomicin, netilmicin...
|
|
WO/2020/003978A1 |
The present invention addresses the problem of providing an agent for enhancing phagocytosis ability of neutrophils, said agent for enhancing phagocytosis ability of neutrophils enhances the phagocytosis ability of neutrophils and thus f...
|
|
WO/2020/002716A1 |
The invention relates to a composition containing 20 to 60% betaine, 5 to 20% extract of Echinacea purpurea, and 10 to 30% extract of Curcuma longa, the percentages being mass percentages relative to the total mass of the composition.
|
|
WO/2019/244929A1 |
Provided is a safer product improved for preventing or ameliorating coccidiosis in poultry, in particular, a composition that does not induce development of the resistance. A feed additive composition for controlling poultry coccidiosis ...
|
|
WO/2019/244133A1 |
The present invention relates to succinic acid and its derivative(s) of Formula (I), their pharmaceutically acceptable salts, polymorphs, solvates, hydrates, co-crystals, isomers and solvates thereof as an active pharmaceutical ingredien...
|
|
WO/2019/242177A1 |
Provided by the present invention is a protein having Toxoplasma immunogenicity, the protein being a cyclophilin mutant protein and consisting of the amino acid sequence as shown in SEQ ID 2. Further provided by the present invention is ...
|
|
WO/2019/245891A1 |
Use of milbemycin oxime for controlling a parasitic infestation on fish from sea lice comprising immersion of fish in water containing a therapeutically effective amount of milbemycin oxime. Compositions comprising milbemycin oxime and m...
|
|
WO/2019/244049A1 |
The present invention provides a compound of Formula (I), or a pharmaceutically acceptable salt thereof: (I) wherein R1, R2, R3, and R4 are as defined herein. The present invention further provides therapeutic uses of these compounds, fo...
|
|
WO/2019/241241A1 |
The present inventions provides systems and methods to manufacture genetically modified lymphocyte cells via the use of linear DNA expression amplicons, and uses of such genetically modified lymphocyte cells to treat disease. The present...
|
|
WO/2019/234112A1 |
The invention relates to an anti-androgen and arsenic trioxide for use in the treatment of prostate cancer.
|
|
WO/2019/230590A1 |
The present invention provides a harmful organism-controlling agent having excellent safety, controlling effect, residual efficacy, etc. Provided are: a pyrazole derivative represented by general formula [1][where, p represents an intege...
|
|
WO/2019/227173A1 |
The present invention relates to compounds that inhibit the interaction between the SPRY-domain containing SOCS box protein and inducible nitric oxide synthase (iNOS). In particular, the present invention relates to compounds of Formula ...
|
|
WO/2019/231805A1 |
The present invention provides methods for making autologous bone marrow hematopoietic progenitors lacking NF-κB p50 protein subunit (p50). The progenitor cells are expanded, exposed to a myeloid cytokine, and provided intravenously to ...
|
|
WO/2019/224606A1 |
The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria para...
|
|
WO/2019/225663A1 |
The present invention addresses the problem of developing and providing a novel agricultural and horticultural insecticidal and acaricidal agent for crop production, such as agricultural and horticultural, in view of factors such as dama...
|
|
WO/2019/224489A1 |
The present invention relates to diltiazem for use as an agent activating the expression of at least one gene coding for type III interferon, for the prevention and/or treatment of infections involving at least one pathogenic micro-organ...
|
|
WO/2019/224607A1 |
The present invention relates to recombinant measles virus expressing proteins of a Plasmodium parasite and their applications, in particular in inducing preventive protection against a Plasmodium infection. The present invention is dire...
|
|
WO/2019/221015A1 |
[Problem] To provide: self-assembled microaggregates that are capable of encapsulating and supporting drugs, etc., using naturally derived plant materials to which the human body and environment are accustomed, and that are capable of be...
|
